Denosumab biosimilar (Teva Pharmaceutical)

地舒单抗生物类似药（Teva Pharmaceutical）

Report date: 2026/04/29 20:02:18

Base Information

Drug NameDenosumab biosimilar (Teva Pharmaceutical)
Drug Alias NamePONLIMSIDEGEVMATVB-009TVB-009P
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[7] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/11/17
Country/TerritoryCzechiaBulgariaUnited States +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTeva Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTeva Pharmaceuticals International GmbhTeva Pharmaceuticals Industries LtdTeva Pharmaceuticals Inc +[6] 
Inactive CompaniesN/A
Active IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A